[1] |
World Health Organization. Global hepatitis report, 2017[EB/OL]. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
|
[2] |
World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022- 2030[EB/OL]. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/full-final-who-ghss-hiv-vh-sti_1-june2022.pdf?sfvrsn=7c074b36_9. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/full-final-who-ghss-hiv-vh-sti_1-june2022.pdf?sfvrsn=7c074b36_9
|
[3] |
World Health Organization. Global health sector strategy on viral hepatitis 2016- 2021: Towards ending viral hepatitis[EB/OL]. https://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng,pdf?ua= 1. https://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng
|
[4] |
GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 796- 829. DOI: 10.1016/S2468-1253(22)00124-8.
|
[5] |
CUI FQ, BLACH S, MANZENGO MINGIEDI C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C[J]. Lancet Gastroenterol Hepatol, 2023, 8( 4): 332- 342. DOI: 10.1016/S2468-1253(22)00386-7.
|
[6] |
COLLABORATORS PO. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study[J]. Lancet Gastroenterol Hepatol, 2023, 8( 10): 879- 907. DOI: 10.1016/S2468-1253(23)00197-8.
|
[7] |
World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2021: accountability for the global health sector strategies, 2016-2021: actions for impact. Geneva: World Health Organization, 2021.
|
[8] |
CDA Foundation. https://cdafound.org/dashboard/polaris/dashboard.html. https://cdafound.org/dashboard/polaris/dashboard.html
|
[9] |
World Health Organization/UNICEF. WHO/UNICEF joint reporting process[EB/OL]. Geneva, 2019. https://www.who.int/treams/immunization- vaccines. https://www.who.int/treams/immunization- vaccines
|
[10] |
COOKE GS, FLOWER B, CUNNINGHAM E, et al. Progress towards elimination of viral hepatitis: A Lancet Gastroenterology& Hepatology Commission update[J]. Lancet Gastroenterol Hepatol, 2024, 9( 4): 346- 365. DOI: 10.1016/S2468-1253(23)00321-7.
|
[11] |
US Center for Disease Control and Prevention. 2023 Viral hepatitis national progress report. 2024[EB/OL]. https://www.cdc.gov/hepatitis/policy/npr/2023/index.htm https://www.cdc.gov/hepatitis/policy/npr/2023/index.htm
|
[12] |
SU X, ZHENG L, ZHANG HM, et al. Secular trends of acute viral hepatitis incidence and mortality in China, 1990 to 2019 and its prediction to 2030: The global burden of disease study 2019[J]. Front Med(Lausanne), 2022, 9: 842088. DOI: 10.3389/fmed.2022.842088.
|
[13] |
YUE TT, ZHANG QQ, CAI T, et al. Trends in the disease burden of HBV and HCV infection in China from 1990-2019[J]. Int J Infect Dis, 2022, 122: 476- 485. DOI: 10.1016/j.ijid.2022.06.017.
|
[14] |
SHI JF, CAO MM, WANG YT, et al. Is it possible to halve the incidence of liver cancer in China by 2050?[J]. Int J Cancer, 2021, 148( 5): 1051- 1065. DOI: 10.1002/ijc.33313.
|
[15] |
CUI FQ, SHEN LP, LI L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23( 5): 765- 772. DOI: 10.3201/eid2305.161477.
|
[16] |
LIANG X, BI SL, YANG WZ, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27( 47): 6550- 6557. DOI: 10.1016/j.vaccine.2009.08.048.
|
[17] |
LIU J, LIANG WN, JING WZ, et al. Countdown to 2030: Eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97( 3): 230- 238. DOI: 10.2471/BLT.18.219469.
|
[18] |
ZHANG GM, MIAO N, ZHENG H, et al. Incidence by age and region of hepatitis B reported in China from 2005 to 2016[J]. Chin J Vaccines Immun, 2018, 24( 2): 121- 126. DOI: 10.19914/j.cjvi.2018.02.001.
张国民, 缪宁, 郑徽, 等. 中国2005—2016年乙型病毒性肝炎报告发病的年龄和地区特征[J]. 中国疫苗和免疫, 2018, 24( 2): 121- 126. DOI: 10.19914/j.cjvi.2018.02.001.
|
[19] |
SO S, TERRAULT N, CONNERS EE. Universal adult hepatitis B screening and vaccination as the path to elimination[J]. JAMA, 2023, 329( 19): 1639- 1640. DOI: 10.1001/jama.2023.2806.
|
[20] |
CONNERS EE, PANAGIOTAKOPOULOS L, HOFMEISTER MG, et al. Screening and testing for hepatitis B virus infection: CDC recommendations-United States, 2023[J]. MMWR Recomm Rep, 2023, 72( 1): 1- 25. DOI: 10.15585/mmwr.rr7201a1.
|
[21] |
SU TH, KAO JH. Improving clinical outcomes of chronic hepatitis B virus infection[J]. Expert Rev Gastroenterol Hepatol, 2015, 9( 2): 141- 154. DOI: 10.1586/17474124.2015.960398.
|